Search research articles
Contact Us
Filters
Showing results (161-170 of 187) with videos related to
Page
of 19
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 4, 2018
A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses
Daniela Matei, Sharad Ghamande, Lynda Roman, et al.
Medicina (Kaunas, Lithuania)
|
February 25, 2022
Expression of Selected Genes and Circulating microRNAs in Patients with Celiac Disease
Elena Maria Domsa, Ioana Berindan-Neagoe, Livia Budisan, et al.
The Journal of Clinical Investigation
|
June 7, 2022
Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer
Siqi Chen, Ping Xie, Matthew Cowan, et al.
Cancer
|
April 11, 2016
Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy
Ursula A Matulonis, Philipp Harter, Charlie Gourley, et al.
British Journal of Cancer
|
November 9, 2016
Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer
Jonathan A Ledermann, Philipp Harter, Charlie Gourley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 16, 2014
The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer
Fang Fang, Joanne Munck, Jessica Tang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 28, 2014
An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer
Michael S Gordon, Francisco Robert, Daniela Matei, et al.
The Lancet. Oncology
|
June 3, 2014
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
Jonathan Ledermann, Philipp Harter, Charlie Gourley, et al.
The Lancet. Oncology
|
September 13, 2016
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial
Jonathan A Ledermann, Philipp Harter, Charlie Gourley, et al.
Methods in Molecular Biology (Clifton, N.J.)
|
November 4, 2016
Complete Transcriptome RNA-Seq
David F B Miller, Pearlly Yan, Fang Fang, et al.
Page
of 19
Search research articles
Search
Showing results (161-170 of 187) with videos related to
Sort By:
Page
of 19
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 4, 2018
A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses
Daniela Matei, Sharad Ghamande, Lynda Roman, et al.
Medicina (Kaunas, Lithuania)
|
February 25, 2022
Expression of Selected Genes and Circulating microRNAs in Patients with Celiac Disease
Elena Maria Domsa, Ioana Berindan-Neagoe, Livia Budisan, et al.
The Journal of Clinical Investigation
|
June 7, 2022
Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer
Siqi Chen, Ping Xie, Matthew Cowan, et al.
Cancer
|
April 11, 2016
Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy
Ursula A Matulonis, Philipp Harter, Charlie Gourley, et al.
British Journal of Cancer
|
November 9, 2016
Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer
Jonathan A Ledermann, Philipp Harter, Charlie Gourley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 16, 2014
The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer
Fang Fang, Joanne Munck, Jessica Tang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 28, 2014
An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer
Michael S Gordon, Francisco Robert, Daniela Matei, et al.
The Lancet. Oncology
|
June 3, 2014
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
Jonathan Ledermann, Philipp Harter, Charlie Gourley, et al.
The Lancet. Oncology
|
September 13, 2016
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial
Jonathan A Ledermann, Philipp Harter, Charlie Gourley, et al.
Methods in Molecular Biology (Clifton, N.J.)
|
November 4, 2016
Complete Transcriptome RNA-Seq
David F B Miller, Pearlly Yan, Fang Fang, et al.
Page
of 19